researchbysubject.bucknell.edu2h
Entrepreneur, Investor, 'Shark Tank' Panelist Kevin O'Leary Next Bucknell Forum Speaker
Presented in partnership with the Perricelli-Gegnas Center for Entrepreneurship & Innovation, O'Leary will appear in the Weis ...
devdiscourse3h
Global Health Crisis: Policy Shifts and Market Turmoil
Current health news highlights significant challenges, including rising maternal deaths in Afghanistan due to U.S. funding ...
Merck Earnings: Gardasil Weighs on 2025 Growth, but Firm Still Undervalued
Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...
Merck's Keytruda Dominance and a Strong Oncology Pipeline Help Support Merck's Wide Moat
Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...
Wall Street Lunch: It's No Yolk - Egg Surcharges Are Here
Among active stocks, Estée Lauder ( EL) is the weakest stock in the S&P after the company’s downbeat outlook into the current fiscal quarter, along with plans to revive the business through job cuts ...
Becker's Hospital Review6h
Merck's 2025 outlook falls on cancer vaccine China shipment pause
Gardasil, a vaccine that prevents cancers caused by human papillomavirus has faced declining sales in China, a key market for the product. Merck's shipping pause aims to reduce excess inventory and ...
Merck projects $64.1B-$65.6B revenue in 2025 amid WINREVAIR growth and GARDASIL rebasing
Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...
Febrile Neutropenia Clinical Trials Review 2024, by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
The "Febrile Neutropenia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trials report provides an overview of the Febrile Neutropenia ...
Aplastic Anemia Global Clinical Trials Review 2024 | Now Available
The "Aplastic Anemia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides top line data relating to the clinical trials ...
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Mercer Advisors Expands in Nashville with Acquisition of $660 Million Financial Partners Group
Mercer Global Advisors, Inc. ("Mercer Advisors"), a national Registered Investment Adviser (RIA), today announced the acquisition of Financial Partners Group ("FPG"), an investment advisory and ...